Skip to main content
Contact Us
Subscribe
E-Edition
35°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
2025 Calendar Photos
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Xoma Royalty Corporation
(NQ:
XOMA
)
33.17
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
106
Open
33.17
Bid (Size)
15.00 (1)
Ask (Size)
38.23 (1)
Prev. Close
33.17
Today's Range
33.17 - 33.17
52wk Range
14.33 - 35.00
Shares Outstanding
11,782,723
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
XOMA Royalty Reports Third Quarter 2024 Financial Results and Highlights Recent Activities
November 07, 2024
From
XOMA Corporation
Via
GlobeNewswire
XOMA Royalty Significantly Expands its Royalty and Milestone Portfolio with the Addition of Over 60 Early-Stage Programs from Twist Bioscience
October 22, 2024
From
XOMA Corporation
Via
GlobeNewswire
Performance
YTD
+58.78%
+58.78%
1 Month
+3.88%
+3.88%
3 Month
+12.44%
+12.44%
6 Month
+31.42%
+31.42%
1 Year
+124.12%
+124.12%
More News
Read More
Zevra’s MIPLYFFA™ (arimoclomol) Receives Approval from U.S. Food and Drug Administration for Use in Patients with Niemann-Pick Disease Type C (NPC)
September 23, 2024
From
XOMA Corporation
Via
GlobeNewswire
Demystifying XOMA: Insights From 5 Analyst Reviews
July 09, 2024
Via
Benzinga
Peeling Back The Layers: Exploring XOMA Through Analyst Insights
May 31, 2024
Via
Benzinga
Cracking The Code: Understanding Analyst Reviews For XOMA
April 29, 2024
Via
Benzinga
XOMA Royalty Declares Quarterly Preferred Stock Dividends
September 23, 2024
From
XOMA Corporation
Via
GlobeNewswire
XOMA Royalty to Present at Upcoming Investor Conferences in September
September 04, 2024
From
XOMA Corporation
Via
GlobeNewswire
XOMA Stock Earnings: XOMA Misses EPS, Beats Revenue for Q2 2024
August 13, 2024
Via
InvestorPlace
XOMA Royalty Reports Second Quarter 2024 Financial Results and Highlights Recent Activities
August 13, 2024
From
XOMA Corporation
Via
GlobeNewswire
FDA Convenes Expert Panel Meeting For Zevra Therapeutics' Arimoclomol, Analyst Optimistic About Approval Despite Small Patient Base
July 09, 2024
Via
Benzinga
Exposures
Product Safety
XOMA Declares Quarterly Preferred Stock Dividends
June 20, 2024
From
XOMA Corporation
Via
GlobeNewswire
XOMA Receives $8.1 Million Milestone Related to Day One Biopharmaceuticals’ Sale of its Priority Review Voucher
June 12, 2024
From
XOMA Corporation
Via
GlobeNewswire
3 Crazy Good Stocks to Buy With $500 Right Now
June 12, 2024
Via
InvestorPlace
XOMA to Present at H.C. Wainwright 2nd Annual Bioconnect Investor Conference at NASDAQ
May 14, 2024
From
XOMA Corporation
Via
GlobeNewswire
XOMA Stock Earnings: XOMA Misses EPS, Beats Revenue for Q1 2024
May 09, 2024
Via
InvestorPlace
XOMA Reports First Quarter 2024 Financial Results and Highlights Recent Activities
May 09, 2024
From
XOMA Corporation
Via
GlobeNewswire
XOMA Adds Economic Interests in Three First-in-Category Assets to its Royalty and Milestone Portfolio Including XACIATO™ (clindamycin phosphate) Vaginal Gel 2%
April 30, 2024
From
XOMA Corporation
Via
GlobeNewswire
XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)
April 25, 2024
From
XOMA Corporation
Via
GlobeNewswire
XOMA Corporation Announces Closing of Tender Offer
April 03, 2024
From
XOMA Corporation
Via
GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Agiliti, Inc. (NYSE – AGTI), Landos Biopharma, Inc. (Nasdaq – LABP), Fusion Pharmaceuticals Inc. (Nasdaq - FUSN), Kinnate Biopharma Inc. (Nasdaq – KNTE)
March 25, 2024
From
Brodsky & Smith LLC
Via
GlobeNewswire
XOMA Declares Quarterly Preferred Stock Dividends
March 21, 2024
From
XOMA Corporation
Via
GlobeNewswire
XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc.
March 19, 2024
From
XOMA Corporation
Via
GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Fusion Pharmaceuticals Inc. (Nasdaq - FUSN), Whole Earth Brands, Inc. (Nasdaq – FREE), Kinnate Biopharma Inc. (Nasdaq – KNTE), Societal CDMO Check Corp. (Nasdaq –
March 19, 2024
From
Brodsky & Smith LLC
Via
GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Whole Earth Brands, Inc. (Nasdaq – FREE), Kinnate Biopharma Inc. (Nasdaq – KNTE), Societal CDMO Check Corp. (Nasdaq – SCTL), California BanCorp (Nasdaq – CALB)
March 13, 2024
From
Brodsky & Smith LLC
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
